Driving and Parking
Directions
750 East Adams Street
Syracuse, NY 13210
Main Campus Phone:
315 464-5540
Public Safety:
315 464-4000
Upstate Connect:
315 464-8668
Search Upstate
Rosemary Rochford, PhD
Current Appointments
- Vice President for Research of Research Administration
- Vice President for Research
Hospital Campus
- Downtown
Research Programs and Affiliations
- Biomedical Sciences Program
- Cancer Research Institute
- Microbiology and Immunology
- Research Pillars
Education & Fellowships
- PhD: University of California at Irvine, 1989
Research Interests
- Etiology of viral-associated malignancies, gammaherpesvirus pathogenesis.
HealthLinkOnAir Radio Interview
5/15/13 How will the NIH grant funding sequester affect local research?3/13/13 Challenges in Cancer Research in Africa
4/29/12 Bird flu virus controversy
Publications
Link to PubMed (Opens new window. Close the PubMed window to return to this page.)
Research Abstract
Infection with Epstein-Barr virus (EBV) is associated with a number of malignancies including endemic Burkitt’s lymphoma (eBL), the most common childhood cancer in sub-Saharan Africa. The current research in my laboratory is directed towards three main areas of investigation. First, we have established a field research project based in Kisumu, Kenya to understand the how the interaction of co-factors including holoendemic malaria in the context of early primary infection with EBV lead to the emergence of eBL. Second, we are utilizing infection of mice with the murine gammaherpesvirus-68 (MHV-68) to examine early events in gammaherpesvirus pathogenesis as well as to model virus-parasite interactions. Finally, we are developing mechanism-based therapies for the treatment of BL and other AIDS-associated non-Hodgkin’s lymphomas that address the unique needs in resource-poor settings using a preclincal model. In this preclinical model, SCID mice are engrafted with BL lines that have been in short-term culture and tagged with luciferase. We are using bioluminescent imaging to monitor tumor growth and response to treatment and to determine whether targeting of angiogenesis by adopting a metronomic schedule of therapy can induce remission and reduce toxicity.